Growth inhibition and differentiation induction in human monoblastic leukaemia cells by I x-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea
1998

Vitamin D and Hydroxyurea in Leukaemia Treatment

publication Evidence: moderate

Author Information

Author(s): M Makishima, J Okabe-Kado, Y Honma

Primary Institution: Saitama Cancer Center Research Institute

Hypothesis

Can the combination of 1,25-dihydroxyvitamin D3 and hydroxyurea enhance differentiation and inhibit growth in human monoblastic leukaemia cells?

Conclusion

The combination of 1,25-dihydroxyvitamin D3 and hydroxyurea significantly enhances growth inhibition and differentiation in human monoblastic leukaemia cells.

Supporting Evidence

  • Hydroxyurea showed the greatest synergistic effects with 1,25(OH)2D3 for growth inhibition and differentiation induction.
  • Combination of 1,25(OH)2D3 with hydroxyurea significantly increased NBT-reducing activity.
  • 1,25(OH)2D3 alone did not induce NBT-reducing activity in U937 cells without hydroxyurea.

Takeaway

This study found that using vitamin D with another drug can help treat a type of blood cancer by stopping the cancer cells from growing and helping them become normal cells.

Methodology

The study examined the effects of various anti-cancer drugs in combination with 1,25-dihydroxyvitamin D3 on the growth and differentiation of human monoblastic leukaemia U937 cells.

Limitations

The clinical use of 1,25-dihydroxyvitamin D3 is limited due to its hypercalcaemic activity.

Statistical Information

P-Value

p<0.0005

Statistical Significance

p<0.0005

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication